Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.12 USD | +6.53% | +1.24% | -27.52% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.52% | 2B | |
+2.43% | 42.75B | |
+47.70% | 41.61B | |
+12.06% | 41.34B | |
-8.83% | 26.59B | |
+6.65% | 25.49B | |
-22.87% | 18.12B | |
+30.41% | 12.24B | |
-2.05% | 11.76B | |
+9.21% | 11B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Oppenheimer Adjusts Intellia Therapeutics Price Target to $90 From $93, Maintains Outperform Rating